Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.65 |
| ▸ | PDE5A | O76074 | 1/20 | 0.65 |
| ▸ | PDE9A | O76083 | 1/20 | 0.65 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.65 |
| ▸ | GYS2 | P54840 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.51 |
| ▸ | PYGM | P11217 | 1/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.51 |
| ▸ | USP7 | Q93009 | 1/20 | 0.51 |
| ▸ | PLCG1 | P19174 | 3/20 | 0.50 |
| ▸ | ACP1 | P24666 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13637888 | 0.93 | POLB (0.68) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL13487367 | 0.93 | POLB (0.68) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL13523646 | 0.88 | POLB (0.63) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL30925714 | 0.83 | GYS2 (0.85) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL13487369 | 0.83 | PDE4D (0.80) | PDE4DPDE5APDE9APDE1BPOLB | |
| SCHEMBL13487370 | 0.83 | PDE4D (0.80) | PDE4DPDE5APDE9APDE1BPOLB | |
| SCHEMBL29934316 | 0.83 | PDE4D (0.80) | PDE4DPDE5APDE9APDE1BPOLB | |
| SCHEMBL22201041 | 0.80 | PTPN1 (0.66) | PDE4DPDE5APDE9APDE1BPOLB | |
| SCHEMBL10014345 | 0.78 | PDE4D (0.74) | PDE4DPDE5APDE9APDE1BPTPN2 | |
| SCHEMBL24433073 | 0.77 | PDE4D (0.73) | PDE4DPDE5APDE9APDE1BGYS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004480-A1 | METHODS AND COMPOSITIONS FOR INHIBITING BIOFILMS | SEQUOIA SCIENCES, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090192327-A1 | METHODS AND COMPOSITIONS FOR INHIBITING BIOFILMS | SEQUOIA SCIENCES, INC. (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004480-A1 | METHODS AND COMPOSITIONS FOR INHIBITING BIOFILMS | MMP9, TIMP3, MMP8 | PDE4D 1661/4885PDE5A 470/4885PDE9A 603/4885 |
| US-20090192327-A1 | METHODS AND COMPOSITIONS FOR INHIBITING BIOFILMS | MMP9, TIMP3, MMP8 | PDE4D 1661/4885PDE5A 470/4885PDE9A 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.